<?xml version="1.0" encoding="ISO-8859-1"?><!DOCTYPE ichicsr>
<ichicsr lang="en">
<ichicsrmessageheader>
<messagetype>ichicsr</messagetype>
<messageformatversion>2.1</messageformatversion>
<messageformatrelease>1.0</messageformatrelease>
<messagenumb>78952</messagenumb>
<messagesenderidentifier>SAAVPROD</messagesenderidentifier>
<messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
<messagedateformat>204</messagedateformat>
<messagedate>20130125152600</messagedate>
</ichicsrmessageheader>
<safetyreport>
<safetyreportversion>1</safetyreportversion>
<safetyreportid>FR-SANOFI-AVENTIS-2013SA004419</safetyreportid>
<primarysourcecountry>FR</primarysourcecountry>
<occurcountry>FR</occurcountry>
<transmissiondateformat>102</transmissiondateformat>
<transmissiondate>20130125</transmissiondate>
<reporttype>1</reporttype>
<serious>1</serious>
<seriousnessdeath>1</seriousnessdeath>
<seriousnesslifethreatening>2</seriousnesslifethreatening>
<seriousnesshospitalization>2</seriousnesshospitalization>
<seriousnessdisabling>2</seriousnessdisabling>
<seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
<receivedateformat>102</receivedateformat>
<receivedate>20130118</receivedate>
<receiptdateformat>102</receiptdateformat>
<receiptdate>20130118</receiptdate>
<fulfillexpeditecriteria>1</fulfillexpeditecriteria>
<companynumb>FR-SANOFI-AVENTIS-2013SA004419</companynumb>
<primarysource>
<reportergivename>PRIVACY</reportergivename>
<reportermiddlename>PRIVACY</reportermiddlename>
<reporterfamilyname>PRIVACY</reporterfamilyname>
<reporterstreet>PRIVACY</reporterstreet>
<reportercity>PRIVACY</reportercity>
<reportercountry>FR</reportercountry>
<qualification>5</qualification>
</primarysource>
<sender>
<sendertype>1</sendertype>
<senderorganization>sanofi-aventis</senderorganization>
<senderdepartment>US Affiliate Pharmacovigilance</senderdepartment>
<sendergivename>Barbara</sendergivename>
<senderfamilyname>Rullo</senderfamilyname>
<senderstreetaddress>55A-435 55 Corporate Drive</senderstreetaddress>
<sendercity>Bridgewater</sendercity>
<senderstate>NJ</senderstate>
<senderpostcode>08807</senderpostcode>
<sendercountrycode>US</sendercountrycode>
<sendertel>9089816698</sendertel>
<sendertelcountrycode>1</sendertelcountrycode>
<senderfax>9089877894</senderfax>
<senderfaxcountrycode>1</senderfaxcountrycode>
<senderemailaddress>Barbara.Rullo@sanofi-aventis.com</senderemailaddress>
</sender>
<receiver>
<receivertype>2</receivertype>
<receiverorganization>ZZFDA</receiverorganization>
<receiverdepartment>Center for Drug Evaluation and Research</receiverdepartment>
<receiverstreetaddress>5600 Fishers lane</receiverstreetaddress>
<receivercity>Rockville</receivercity>
<receiverstate>MD</receiverstate>
<receiverpostcode>20857</receiverpostcode>
<receivercountrycode>US</receivercountrycode>
<receivertel>3018273237</receivertel>
<receivertelcountrycode>1</receivertelcountrycode>
<receiveremailaddress>aersesub@cder.fda.gov</receiveremailaddress>
</receiver>
<patient>
<patientinitial>PRIVACY</patientinitial>
<patientonsetage>60</patientonsetage>
<patientonsetageunit>801</patientonsetageunit>
<patientagegroup>5</patientagegroup>
<patientsex>2</patientsex>
<patientdeath>
<patientdeathdateformat>102</patientdeathdateformat>
<patientdeathdate>20130105</patientdeathdate>
<patientautopsyyesno>3</patientautopsyyesno>
<patientdeathcause>
<patientdeathreportmeddraversion>15.1</patientdeathreportmeddraversion>
<patientdeathreport>10037377</patientdeathreport>
</patientdeathcause>
</patientdeath>
<reaction>
<primarysourcereaction>pulmonary embolism</primarysourcereaction>
<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
<reactionmeddrallt>10037377</reactionmeddrallt>
<termhighlighted>4</termhighlighted>
<reactionfirsttime>1</reactionfirsttime>
<reactionfirsttimeunit>802</reactionfirsttimeunit>
<reactionoutcome>5</reactionoutcome>
</reaction>
<drug>
<drugcharacterization>1</drugcharacterization>
<medicinalproduct>LOVENOX</medicinalproduct>
<drugbatchnumb>UNKNOWN</drugbatchnumb>
<drugauthorizationnumb>NDA 20-164</drugauthorizationnumb>
<drugstructuredosagenumb>6000</drugstructuredosagenumb>
<drugstructuredosageunit>025</drugstructuredosageunit>
<drugseparatedosagenumb>1</drugseparatedosagenumb>
<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
<drugintervaldosagedefinition>804</drugintervaldosagedefinition>
<drugdosageform>INJECTION</drugdosageform>
<drugadministrationroute>058</drugadministrationroute>
<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
<drugindication>10043634</drugindication>
<drugstartperiod>1</drugstartperiod>
<drugstartperiodunit>802</drugstartperiodunit>
<actiondrug>6</actiondrug>
<activesubstance>
<activesubstancename>ENOXAPARIN SODIUM</activesubstancename>
</activesubstance>
</drug>
<summary>
<narrativeincludeclinical>This serious unsolicited report from France (Local reference number: 2013-FRA-000405) was received on 18-Jan-2013 from a consumer for his mother and concerns a 60 year old female patient who died due to pulmonary embolism whilst receiving treatment with enoxaparin sodium (Lovenox) for thrombosis prophylaxis.

On an unknown date, the patient had experienced ankle fracture. She was immobilized and was using a wheelchair. On an unknown date, she started receiving subcutaneous enoxaparin sodium injection 6000 IU daily (batch/ lot number and expiry date not specified). The patient had injected the injections of enoxaparin herself. One month after enoxaparin initiation, she experienced pulmonary embolism leading to death on 05-Jan-2013.  It was unknown if Autopsy was done.

Patient&#xc2bf;s medical history and concomitant medication, if any, were not provided.

French imputability: C1S1B2

No further information was provided.</narrativeincludeclinical>
<sendercomment>Sanofi-Aventis company comment dated 21-Jan-2013: Based on the available information causal role of enoxaparin sodium cannot be denied for the event of pulmonary embolism leading to fatal outcome, however alternative explanation for the same is patient&#xc2bf;s underlying condition.</sendercomment>
</summary>
</patient>
</safetyreport>
</ichicsr>
